Complement inhibitors and FcRn blockers improve outcomes in AChR-Ab+ generalized myasthenia gravis
New Drugs Double Your Chance of Getting Better
A meta-analysis of 739 adults in RCTs and 588 in OLEs with acetylcholine receptor antibody-positive generalized myasthenia gravis found that…
New drugs for generalized myasthenia gravis double the odds of meaningful improvement while reducing the need for rescue therapy and severe …
Case report: Ravulizumab successfully treated COVID-19-triggered complement-mediated TMA in a kidney transplant recipient
Doctors report a single case where ravulizumab treated a rare blood disorder after COVID-19 in a kidney transplant patient.
A case report describes a 75-year-old kidney transplant recipient who developed complement-mediated thrombotic microangiopathy (CM-TMA) trig…
A kidney transplant patient with COVID-19 improved after doctors treated a rare blood disorder with ravulizumab, showing age shouldn't block…